ABK Biomedical just closed a $35M Series D led by J.P. Morgan Life Sciences Private Capital, with continued backing from F-Prime Capital, Santé Ventures, Eight Roads Ventures, and Varian Medical Systems. That’s not pocket change; it’s a power move from Halifax to the global interventional oncology stage. When a company turns “invisible” therapy into something you can literally see under X-ray, CT, or PET/CT, you know they’re not playing small-ball science.
ABK Biomedical was born out of Dalhousie University in 2012 thanks to three minds who refused to color inside the lines, Dr. Robert Abraham, Dr. Daniel Boyd, and Dr. Sharon Kehoe. Fast-forward 13 years and this once-academic spin-off is now building a clinical empire out of glass microspheres that don’t just treat tumors; they show up, light up, and deliver precision like a sniper with a microscope.
Leading the charge is President & CEO Michael Mangano, who’s seen more medtech boardrooms than most people see coffee shops. Add Chief Business Officer Gary Donofrio, Chief Medical Officer Dr. Aravind Arepally, CFO Mike Tyson, and a leadership crew stacked with veterans like Marc Gregoire, David Dobrowski, Anthony Headley, and Dr. Lucy Bataneant, and you’ve got a team that reads like a masterclass in commercializing breakthrough science.
The company’s two flagship devices tell the story best. Easi-Vue embolic microspheres earned FDA 510(k) clearance in 2022 for treating arteriovenous malformations and hypervascular tumors. Eye90 microspheres scored Breakthrough Device Designation in 2023 for tackling unresectable hepatocellular carcinoma, then hit its pivotal IDE study with the first patient treated in Oct 2023. By Nov 2024, the FDA had already green-lit Stage 2 enrollment, rare speed in this game.
With two GMP facilities in Halifax, ISO13485:2016 certification, and a long-term irradiation partnership with Missouri University Research Reactor, ABK’s not just talking innovation; they’re manufacturing it.
The $35M fuel will drive the Route90 pivotal trial toward PMA submission, scale production, and prep for Eye90’s commercial debut. The Y90 radioembolization space is one of the fastest-rising corners of interventional oncology, valued at $2.53 B in 2023 and on track for $4.24 B by 2029. ABK’s plan is simple: capture share, redefine precision, and make “imageable therapy” the new normal.
